# High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

Study · id `cardio:ct-nct03403556` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03403556](<https://clinicaltrials.gov/study/NCT03403556>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03403556

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

## Technical summary

Registry record NCT03403556. Randomized; no masking; primary purpose treatment. Start 2018-03-27 (actual); primary completion 2021-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT03403556, source copy `cardio:ctgov-nct03403556-2020-12-14`, retrieved 2026-10-26)
- Started: 2018-03-27 (actual) (ClinicalTrials.gov record NCT03403556, source copy `cardio:ctgov-nct03403556-2020-12-14`, retrieved 2026-10-26)
- Primary completion: 2021-10 (anticipated) (ClinicalTrials.gov record NCT03403556, source copy `cardio:ctgov-nct03403556-2020-12-14`, retrieved 2026-10-26)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03403556, source copy `cardio:ctgov-nct03403556-2020-12-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03403556, source copy `cardio:ctgov-nct03403556-2020-12-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03403556-2020-12-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Type 2 Diabetes
- Intervention (Drug): Rosuvamibe
- Intervention (Drug): Monorova
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

## Provenance

Content hash: 6e5ca4a0ef2507e09fc3ac48f82c4a00c641f18d8f212b1717015fe1246cecd5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
